SELLAS Life Sciences Group (SLS) to Release Quarterly Earnings on Tuesday

Key Points

• SELLAS Life Sciences Group is set to announce its Q2 2025 earnings on Tuesday, August 12th, with analysts expecting a loss of ($0.08) per share.
• The company's stock increased by 2.8% to $1.64, with a market capitalization of approximately $163.14 million.
• Maxim Group recently raised the price target for SELLAS Life Sciences from $4.00 to $7.00 and assigned it a "buy" rating.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. On average, analysts expect SELLAS Life Sciences Group to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SELLAS Life Sciences Group Stock Down 1.9%

Shares of SELLAS Life Sciences Group stock opened at $1.59 on Thursday. The firm has a market cap of $158.65 million, a PE ratio of -4.18 and a beta of 2.26. The company's fifty day simple moving average is $1.78 and its two-hundred day simple moving average is $1.48. SELLAS Life Sciences Group has a 12-month low of $0.77 and a 12-month high of $2.27.

Analyst Upgrades and Downgrades

Separately, Maxim Group lifted their price objective on SELLAS Life Sciences Group from $4.00 to $7.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th.

Insider Buying and Selling

In other SELLAS Life Sciences Group news, Director Jane Wasman bought 20,000 shares of the firm's stock in a transaction on Friday, May 30th. The stock was acquired at an average price of $1.69 per share, with a total value of $33,800.00. Following the completion of the purchase, the director owned 30,400 shares of the company's stock, valued at approximately $51,376. This trade represents a 192.31% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.40% of the stock is owned by insiders.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.